Research programme: proto-oncogene protein c-met inhibitors - Bayer HealthCare Pharmaceuticals

Drug Profile

Research programme: proto-oncogene protein c-met inhibitors - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY 853474; MET inhibitors - Bayer HealthCare Pharmaceuticals

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
  • 16 Apr 2016 BAY 853474 is still in preclinical development for Cancer in Germany
  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top